
## Angela Vincent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8328013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	10.2	2,782
2	Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain, 2010, 133, 2734-2748.	7.6	1,158
3	Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infectious Diseases, The, 2010, 10, 835-844.	9.1	1,107
4	Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine, 2001, 7, 365-368.	30.7	1,083
5	Potassium channel antibodyâ€associated encephalopathy: a potentially immunotherapyâ€responsive form of limbic encephalitis. Brain, 2004, 127, 701-712.	7.6	1,072
6	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain, 2010, 133, 1655-1667.	7.6	900
7	The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain, 2020, 143, 3104-3120.	7.6	880
8	Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of Neurology, 2011, 69, 892-900.	5.3	751
9	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695
10	Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurology, The, 2011, 10, 759-772.	10.2	549
11	Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain, 2012, 135, 1622-1638.	7.6	549
12	Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, 140, 3128-3138.	7.6	527
13	Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies. JAMA Neurology, 2014, 71, 276.	9.0	519
14	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain, 2010, 133, 349-361.	7.6	480
15	Morvan syndrome: Clinical and serological observations in 29 cases. Annals of Neurology, 2012, 72, 241-255.	5.3	470
16	CLINICAL, PATHOLOGICAL, HLA ANTIGEN AND IMMUNOLOGICAL EVIDENCE FOR DISEASE HETEROGENEITY IN MYASTHENIA GRAVIS. Brain, 1980, 103, 579-601.	7.6	463
17	Serologic diagnosis of NMO. Neurology, 2012, 78, 665-671.	1.1	454
18	lgG1 antibodies to acetylcholine receptors in â€~seronegative' myasthenia gravisâ€. Brain, 2008, 131, 1940-1952.	7.6	438

#	Article	IF	CITATIONS
19	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	7.6	430
20	Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Annals of Neurology, 2010, 67, 470-478.	5.3	429
21	Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1246-1252.	1.9	422
22	Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain, 2002, 125, 1887-1895.	7.6	419
23	Acquired neuromyotonia: Evidence for autoantibodies directed against K <sup>+</sup> channels of peripheral nerves. Annals of Neurology, 1995, 38, 714-722.	5.3	414
24	Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain, 2008, 131, 3072-3080.	7.6	397
25	Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Annals of Neurology, 2004, 55, 580-584.	5.3	391
26	Clinical aspects of MuSK antibody positive seronegative MG. Neurology, 2003, 60, 1978-1980.	1.1	389
27	Potassium channel antibodies in two patients with reversible limbic encephalitis. Annals of Neurology, 2001, 50, 73-78.	5.3	381
28	GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nature Genetics, 2013, 45, 1061-1066.	21.4	380
29	Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nature Medicine, 2007, 13, 1483-1489.	30.7	373
30	Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain, 2013, 136, 3151-3162.	7.6	373
31	Cerebellar Ataxia With Anti–Glutamic Acid Decarboxylase Antibodies. Archives of Neurology, 2001, 58, 225.	4.5	371
32	Unravelling the pathogenesis of myasthenia gravis. Nature Reviews Immunology, 2002, 2, 797-804.	22.7	366
33	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain, 2012, 135, 1834-1849.	7.6	361
34	Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurology, The, 2014, 13, 195-205.	10.2	352
35	Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain, 2001, 124, 2417-2426.	7.6	347
36	AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME. Lancet, The, 1981, 318, 224-226.	13.7	337

#	Article	IF	CITATIONS
37	Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Annals of Neurology, 1997, 41, 238-246.	5.3	328
38	PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY. Neurology, 2008, 71, 1291-1292.	1.1	324
39	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e89.	6.0	322
40	Interferon Beta Treatment in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1016-7.	4.5	295
41	Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 7636-7640.	7.1	286
42	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology, 2008, 4, 202-214.	2.5	286
43	Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology, 2011, 258, 686-688.	3.6	277
44	The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain, 2018, 141, 348-356.	7.6	272
45	Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 638-645.	1.9	261
46	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, 913-9.	4.5	259
47	Function of circulating antibody to acetylcholine receptor in myasthenia gravis. Neurology, 1978, 28, 266-266.	1.1	258
48	Immunology of acetylcholine receptors in relation to myasthenia gravis Physiological Reviews, 1980, 60, 756-824.	28.8	255
49	Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature, 1985, 317, 737-739.	27.8	253
50	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry,the, 2020, 7, 93-108.	7.4	252
51	Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain, 2019, 142, 2303-2318.	7.6	248
52	Dok-7 Mutations Underlie a Neuromuscular Junction Synaptopathy. Science, 2006, 313, 1975-1978.	12.6	247
53	Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Journal of the Neurological Sciences, 1997, 147, 35-42.	0.6	236
54	An improved diagnostic assay for Lambert-Eaton myasthenic syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 85-87.	1.9	232

#	Article	IF	CITATIONS
55	Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Annals of Neurology, 1987, 22, 212-222.	5.3	229
56	Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet, The, 1991, 338, 75-77.	13.7	228
57	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
58	Nâ€methylâ€ <scp>D</scp> â€aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Annals of Neurology, 2009, 66, 704-709.	5.3	223
59	Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 748-755.	1.9	217
60	Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology, The, 2003, 2, 99-106.	10.2	216
61	Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Annals of Neurology, 2005, 57, 444-448.	5.3	216
62	Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Annals of Neurology, 2006, 59, 178-181.	5.3	213
63	Postsynaptic Abnormalities at the Neuromuscular Junctions of Utrophin-deficient Mice. Journal of Cell Biology, 1997, 136, 883-894.	5.2	212
64	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	1.6	210
65	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain, 2017, 140, 617-627.	7.6	208
66	Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e81.	6.0	205
67	Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e163.	6.0	203
68	MYASTHENIA GRAVIS WITHOUT ACETYLCHOLINE-RECEPTOR ANTIBODY: A DISTINCT DISEASE ENTITY. Lancet, The, 1986, 327, 116-119.	13.7	202
69	Immunology of disorders of neuromuscular transmission. Acta Neurologica Scandinavica, 2006, 113, 1-7.	2.1	201
70	Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013, 54, 1028-1035.	5.1	199
71	Maternal neuronal antibodies associated with autism and a language disorder. Annals of Neurology, 2003, 53, 533-537.	5.3	193
72	<i>N</i> â€methylâ€ <i>D</i> â€aspartate receptor antibodies in post–herpes simplex virus encephalitis neurological relapse. Movement Disorders, 2014, 29, 90-96.	3.9	192

#	Article	IF	CITATIONS
73	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. PLoS Medicine, 2007, 4, e133.	8.4	187
74	Evidence of underdiagnosis of myasthenia gravis in older people. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1105-1108.	1.9	180
75	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.1	177
76	Neuroinflammation: Ways in Which the Immune System Affects the Brain. Neurotherapeutics, 2015, 12, 896-909.	4.4	170
77	Acetylcholine receptor antibody synthesis by thymic lymphocytes. Neurology, 1981, 31, 935-935.	1.1	170
78	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	0.6	169
79	An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature, 2007, 448, 934-937.	27.8	167
80	Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends in Neurosciences, 1989, 12, 496-502.	8.6	165
81	Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravis. Annals of Neurology, 2005, 57, 289-293.	5.3	164
82	MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain, 2006, 129, 1481-1492.	7.6	160
83	Autoimmunity against the $\hat{l}^22$ adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain, 2011, 152, 2690-2700.	4.2	160
84	Cellâ€ <b>s</b> urface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Annals of Neurology, 2014, 76, 168-184.	5.3	159
85	Antibodies to GABA <sub>A</sub> receptor $\hat{I}\pm 1$ and $\hat{I}^3 2$ subunits. Neurology, 2015, 84, 1233-1241.	1.1	159
86	Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy. Archives of Neurology, 2009, 66, 458-64.	4.5	158
87	Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet, The, 1995, 346, 24-25.	13.7	156
88	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology, 2017, 89, 269-278.	1.1	155
89	Neutrophil protease inhibition reduces neuromyelitis optica–immunoglobulin G–induced damage in mouse brain. Annals of Neurology, 2012, 71, 323-333.	5.3	153
90	Management of suspected viral encephalitis in children – Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group National Guidelines. Journal of Infection, 2012, 64, 449-477.	3.3	152

#	Article	IF	CITATIONS
91	Mutations in Different Functional Domains of the Human Muscle Acetylcholine Receptor  Subunit in Patients with the Slow-Channel congenital Myasthenic Syndrome. Human Molecular Genetics, 1997, 6, 767-774.	2.9	147
92	Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function Journal of Clinical Investigation, 1996, 98, 2358-2363.	8.2	146
93	Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain, 2018, 141, 13-36.	7.6	145
94	Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain, 2006, 129, 1570-1584.	7.6	144
95	Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry,the, 2017, 4, 42-48.	7.4	143
96	Anti-acetylcholine receptor antibodies Journal of Neurology, Neurosurgery and Psychiatry, 1980, 43, 590-600.	1.9	142
97	Limbic encephalitis in children and adolescents. Archives of Disease in Childhood, 2011, 96, 186-191.	1.9	140
98	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
99	MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE, 2013, 8, e80695.	2.5	138
100	Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clinical and Experimental Immunology, 1982, 49, 257-65.	2.6	136
101	IN-VITRO SYNTHESIS OF ANTI-ACETYLCHOLINE-RECEPTOR ANTIBODY BY THYMIC LYMPHOCYTES IN MYASTHENIA GRAVIS. Lancet, The, 1978, 311, 305-307.	13.7	134
102	Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Research, 2006, 71, 135-141.	1.6	133
103	Ion channels in genetic and acquired forms of epilepsy. Journal of Physiology, 2013, 591, 753-764.	2.9	130
104	Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Current Opinion in Neurology, 2005, 18, 519-525.	3.6	127
105	Morvan's syndrome associated with voltage-gated K channel antibodies. Neurology, 2000, 54, 771-771.	1.1	126
106	Myasthenia gravis: a clinical-immunological update. Journal of Neurology, 2016, 263, 826-834.	3.6	124
107	Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 353-361.	1.9	124
108	The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Annals of Neurology, 2000, 47, 162-170.	5.3	123

#	Article	IF	CITATIONS
109	Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British Journal of Pharmacology, 2005, 146, 1027-1039.	5.4	123
110	Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific lgG4 instead of lgG1. Journal of Neuroimmunology, 2008, 195, 151-156.	2.3	122
111	Antiglycine-receptor encephalomyelitis with rigidity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1399-1401.	1.9	121
112	Congenital myasthenia: End-plate acetylcholine receptors and electrophysiology in five cases. Muscle and Nerve, 1981, 4, 306-318.	2.2	119
113	Teratogen update: Maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology, 2000, 62, 332-341.	1.6	119
114	Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology, 2004, 63, 43-50.	1.1	119
115	Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability. Neuron, 2018, 97, 806-822.e10.	8.1	119
116	Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurology, 2015, 72, 642.	9.0	118
117	Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. Journal of Neuroimmunology, 2005, 165, 166-171.	2.3	117
118	ACETYLCHOLINE RECEPTORS AND END-PLATE ELECTROPHYSIOLOGY IN MYASTHENIA GRAVIS. Brain, 1978, 101, 345-368.	7.6	115
119	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. Pediatrics, 2015, 135, e974-e984.	2.1	115
120	Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Research, 2016, 5, 1513.	1.6	115
121	Autoimmune Disorders of Neuronal Potassium Channels. Annals of the New York Academy of Sciences, 2003, 998, 202-210.	3.8	114
122	Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology, 2006, 66, 1772-1774.	1.1	114
123	Myasthenia Gravis Thymus. American Journal of Pathology, 2007, 171, 893-905.	3.8	113
124	Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Developmental Medicine and Child Neurology, 2011, 53, 1053-1057.	2.1	113
125	Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Experimental Neurology, 2012, 234, 506-512.	4.1	112
126	N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Archives of Disease in Childhood, 2015, 100, 521-526.	1.9	112

#	Article	IF	CITATIONS
127	The Association of Bullous Pemphigoid With Cerebrovascular Disease and Dementia. Archives of Dermatology, 2010, 146, 1251-4.	1.4	111
128	Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis. Archives of Neurology, 2012, 69, 994-1001.	4.5	111
129	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	1.9	108
130	Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1996, 71, 173-177.	2.3	106
131	Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 625-630.	1.9	106
132	Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 437-440.	1.9	105
133	Autoimmune Channelopathies and Related Neurological Disorders. Neuron, 2006, 52, 123-138.	8.1	104
134	Antibodies in Myasthenia Gravis and Related Disorders. Annals of the New York Academy of Sciences, 2003, 998, 324-335.	3.8	103
135	The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Current Opinion in Neurology, 2010, 23, 144-150.	3.6	103
136	IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody- mediated disease. European Journal of Immunology, 1998, 28, 2487-2497.	2.9	101
137	Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology, 2001, 57, 1579-1582.	1.1	101
138	Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies. JAMA Neurology, 2013, 70, 1375.	9.0	100
139	Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia, 2011, 52, 121-131.	5.1	99
140	VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology, 2011, 76, 1252-1255.	1.1	99
141	Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology, 2015, 85, 235-239.	1.1	99
142	Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease. Lancet, The, 1997, 350, 1596-1597.	13.7	97
143	Clinical relevance of serum antibodies to extracellular <i>N</i> -methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	1.9	97
144	NMDA Receptor Antibody Encephalitis. Current Neurology and Neuroscience Reports, 2011, 11, 298-304.	4.2	96

#	Article	IF	CITATIONS
145	Passive transfer of seronegative myasthenia gravis to mice. Muscle and Nerve, 1994, 17, 1393-1400.	2.2	95
146	Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder. Neurology, 2016, 86, 79-87.	1.1	95
147	Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunological Reviews, 1998, 164, 157-168.	6.0	94
148	Antibody-mediated encephalitis: a treatable cause of schizophrenia. British Journal of Psychiatry, 2012, 200, 92-94.	2.8	94
149	Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7343-7347.	7.1	93
150	<i>Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies</i> . Annals of the New York Academy of Sciences, 2008, 1132, 84-92.	3.8	93
151	Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Annals of Neurology, 1997, 41, 423-431.	5.3	92
152	Progressive encephalomyelitis with rigidity and myoclonus. Neurology, 2011, 77, 439-443.	1.1	92
153	lgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. Journal of Autoimmunity, 2017, 77, 104-115.	6.5	92
154	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. Journal of Immunology, 2013, 191, 2999-3005.	0.8	90
155	Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 470-472.	1.9	90
156	Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain, 2017, 140, 1212-1219.	7.6	89
157	Anti-N-methyl-D-aspartate receptor antibodies: A potentially treatable cause of encephalitis in the intensive care unit. Critical Care Medicine, 2010, 38, 679-682.	0.9	88
158	Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model. Brain, 2015, 138, 3159-3167.	7.6	88
159	A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18 Journal of Clinical Investigation, 1996, 97, 1155-1164.	8.2	87
160	Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. Archives of Neurology, 2000, 57, 527.	4.5	87
161	Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology, 1983, 33, 1276-1276.	1.1	86
162	NMDA receptor antibodies associated with distinct white matter syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e2.	6.0	85

#	Article	IF	CITATIONS
163	Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. International MS Journal, 2008, 15, 99-105.	0.3	84
164	The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. Frontiers in Molecular Neuroscience, 2020, 13, 610964.	2.9	83
165	Seronegative Myasthenia Gravis. Seminars in Neurology, 2004, 24, 125-133.	1.4	82
166	Autoimmune synaptopathies. Nature Reviews Neuroscience, 2016, 17, 103-117.	10.2	81
167	How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Archives of Disease in Childhood, 2014, 99, 539-542.	1.9	79
168	Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics, 2016, 13, 147-162.	4.4	78
169	CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. Journal of the Neurological Sciences, 2008, 268, 74-77.	0.6	76
170	The search for new antigenic targets in myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 123-128.	3.8	76
171	Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia, 2013, 54, 1036-1045.	5.1	76
172	Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes Journal of Clinical Investigation, 1994, 93, 1361-1369.	8.2	74
173	AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology, 2002, 59, 1682-1688.	1.1	73
174	Antibody Heterogeneity and Specificity in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1987, 505, 106-120.	3.8	72
175	Autoimmune mediated neuromuscular junction defects. Current Opinion in Neurology, 2010, 23, 489-495.	3.6	72
176	Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. Journal of Clinical Investigation, 1999, 103, 1031-1038.	8.2	72
177	A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology, 1996, 47, 1552-1555.	1.1	71
178	Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. FEBS Journal, 2000, 267, 6717-6728.	0.2	71
179	Febrile Infection-Related Epilepsy Syndrome without Detectable Autoantibodies and Response to Immunotherapy: A Case Series and Discussion of Epileptogenesis in FIRES. Neuropediatrics, 2012, 43, 209-216.	0.6	71
180	Primary structure of the human muscle acetylcholine receptor. cDNA cloning of the gamma and e subunits. FEBS Journal, 1993, 215, 229-238.	0.2	70

#	Article	IF	CITATIONS
181	Sjögren's syndrome myelopathy: spinal cord involvement in Sjögren's syndrome might be a manifestation of neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1062-1068.	3.0	70
182	Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 456-461.	1.9	70
183	Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. Pain, 2014, 155, 2408-2417.	4.2	70
184	A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes Journal of Clinical Investigation, 1998, 101, 2268-2277.	8.2	70
185	Successful treatment of anti-N-methyl-D-aspartate receptor encephalitis presenting with catatonia. Archives of Disease in Childhood, 2009, 94, 314-316.	1.9	69
186	<i>Autoimmunizing Mechanisms in Thymoma and Thymus</i> *. Annals of the New York Academy of Sciences, 2008, 1132, 163-173.	3.8	68
187	Caspr2 Antibodies in Patients with Thymomas. Journal of Thoracic Oncology, 2010, 5, S277-S280.	1.1	68
188	Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. Biological Psychiatry, 2017, 82, 766-772.	1.3	67
189	Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain, 2005, 128, 2327-2337.	7.6	66
190	Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia, 2011, 52, 12-17.	5.1	66
191	Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia, 2014, 55, 414-422.	5.1	66
192	Spontaneous production of anti-IFN-Â and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. International Immunology, 2003, 15, 903-913.	4.0	65
193	Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. Journal of Neurology, 2011, 258, 464-470.	3.6	65
194	Autoimmune channelopathies. Nature Clinical Practice Neurology, 2005, 1, 22-33.	2.5	64
195	Neuromuscular transmission after immunization against acetylcholine receptors. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1975, 189, 57-68.	1.8	63
196	Seronegative Myasthenia Gravis: Evidence for Plasma Factor(s) Interfering with Acetylcholine Receptor Function. Annals of the New York Academy of Sciences, 1993, 681, 529-538.	3.8	63
197	Scenarios for Autoimmunization of T and B Cells in Myasthenia Gravis. Annals of the New York Academy of Sciences, 2003, 998, 237-256.	3.8	63
198	Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophrenia Research, 2014, 160, 193-195.	2.0	62

#	Article	IF	CITATIONS
199	Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. , 2000, 92, 1-6.		61
200	Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Movement Disorders, 2006, 21, 1737-1741.	3.9	61
201	Genes at the junction—candidates for congenital myasthenic syndromes. Trends in Neurosciences, 1997, 20, 15-22.	8.6	60
202	Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 714-718.	1.9	60
203	Human African Trypanosomiasis Presenting at Least 29 Years after Infection—What Can This Teach Us about the Pathogenesis and Control of This Neglected Tropical Disease?. PLoS Neglected Tropical Diseases, 2014, 8, e3349.	3.0	60
204	Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders, 2004, 14, 356-364.	0.6	59
205	Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1069-1076.	3.0	59
206	Immunological Heterogeneity and Cellular Mechanisms in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1987, 505, 12-26.	3.8	58
207	Autoantibodies to ion channels at the neuromuscular junction. Autoimmunity Reviews, 2003, 2, 94-100.	5.8	58
208	Clinical relevance of voltage-gated potassium channel–complex antibodies in children. Neurology, 2015, 85, 967-975.	1.1	57
209	Neuronal Surface and Glutamic Acid Decarboxylase Autoantibodies in Nonparaneoplastic Stiff Person Syndrome. JAMA Neurology, 2013, 70, 1140.	9.0	56
210	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 2019, 10, 1028.	2.4	56
211	MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. Journal of Neuroimmunology, 2005, 170, 41-48.	2.3	55
212	Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle and Nerve, 2006, 33, 568-570.	2.2	55
213	Do Neuronal Autoantibodies Cause Psychosis? A Neuroimmunological Perspective. Biological Psychiatry, 2014, 75, 269-275.	1.3	55
214	Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 34-38.	1.1	54
215	Suspected Limbic Encephalitis and Seizure in Cats Associated with Voltageâ€Gated Potassium Channel ( <scp>VGKC</scp> ) Complex Antibody. Journal of Veterinary Internal Medicine, 2013, 27, 212-214.	1.6	54
216	Autoantibodies to neuronal antigens in children with newâ€onset seizures classified according to the revised <scp>ILAE</scp> organization of seizures and epilepsies. Epilepsia, 2013, 54, 2091-2100.	5.1	54

#	Article	IF	CITATIONS
217	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	2.3	54
218	Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Experimental Neurology, 2015, 270, 66-71.	4.1	54
219	Postencephalitic epilepsy and drugâ€resistant epilepsy after infectious and antibodyâ€associated encephalitis in childhood: Clinical and etiologic risk factors. Epilepsia, 2016, 57, e7-e11.	5.1	54
220	Monoclonal antibodies that distinguish between normal and denervated human acetylcholine re receptor. Journal of Neuroimmunology, 1986, 11, 223-235.	2.3	53
221	Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. Journal of Neuroimmunology, 2001, 113, 153-162.	2.3	53
222	Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomy. Neurology, 2011, 76, 303-304.	1.1	53
223	IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e357.	6.0	53
224	Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain, 2004, 127, 269-279.	7.6	52
225	FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurologica Scandinavica, 2005, 111, 338-343.	2.1	52
226	Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. Journal of Neuroimmunology, 1995, 56, 65-76.	2.3	51
227	Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. Neurology India, 2011, 59, 47.	0.4	51
228	Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. Journal of Neurology, 2012, 259, 1566-1573.	3.6	51
229	Progressive Encephalomyelitis With Rigidity and Myoclonus. JAMA Neurology, 2013, 70, 498.	9.0	51
230	Neuromuscular junction disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 447-466.	1.8	51
231	Isolated new onset â€~atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Journal of Neurology, 2016, 263, 370-379.	3.6	51
232	Antiglycine receptor antibody related disease: a case series and literature review. European Journal of Neurology, 2018, 25, 1290-1298.	3.3	51
233	Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the ε subunit. Neuroscience Letters, 1996, 207, 57-60.	2.1	50
234	Pathogenic autoantibodies to neuronal proteins in neurological disorders. Journal of Neuroimmunology, 1999, 100, 169-180.	2.3	50

#	Article	IF	CITATIONS
235	End-plate gamma- and varepsilon-subunit mRNA levels in AChR deficiency syndrome due to varepsilon-subunit null mutations. Brain, 2001, 124, 1362-1372.	7.6	50
236	Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain, 2006, 129, 2773-2783.	7.6	50
237	Autoimmune disorders of the neuromuscular junction. Current Opinion in Pharmacology, 2009, 9, 336-340.	3.5	50
238	Fetal acetylcholine receptor inactivation syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e57.	6.0	50
239	Neuroimaging in encephalitis: analysis of imaging findings and interobserver agreement. Clinical Radiology, 2016, 71, 1050-1058.	1.1	49
240	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1021-1026.	1.9	49
241	Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. Journal of Neuroimmunology, 1988, 19, 141-148.	2.3	48
242	Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. International Immunology, 1997, 9, 1311-1318.	4.0	48
243	Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scandinavian Journal of Gastroenterology, 2007, 42, 1289-1293.	1.5	48
244	FETAL ACETYLCHOLINE RECEPTOR INACTIVATION SYNDROME AND MATERNAL MYASTHENIA GRAVIS. Neurology, 2008, 71, 2010-2012.	1.1	48
245	NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2012, 259, 1979-1981.	3.6	48
246	Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 692-694.	1.9	48
247	Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice. European Journal of Immunology, 1993, 23, 973-976.	2.9	47
248	Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain, 2002, 125, 1309-1319.	7.6	47
249	Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain, 2019, 142, 3398-3410.	7.6	47
250	Voltage-gated potassium channel–complex autoimmunity and associated clinical syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 185-197.	1.8	46
251	High sensitivity and specificity in proposed clinical diagnostic criteria for antiâ€ <i>N</i> â€methylâ€ <scp>D</scp> â€aspartate receptor encephalitis. Developmental Medicine and Child Neurology, 2017, 59, 1256-1260.	2.1	46
252	Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero. Acta Neuropathologica, 2017, 134, 567-583.	7.7	46

#	Article	IF	CITATIONS
253	Myasthenia gravis. Neurology, 1986, 36, 612-612.	1.1	46
254	Antibodies to Acetylcholine Receptor in Parous Women with Myasthenia: Evidence for Immunization by Fetal Antigen. Laboratory Investigation, 2002, 82, 1407-1417.	3.7	45
255	Rhabdomyosarcoma Lysis by T Cells Expressing a Human Autoantibody-Based Chimeric Receptor Targeting the Fetal Acetylcholine Receptor. Cancer Research, 2006, 66, 24-28.	0.9	45
256	Collagen Q – A potential target for autoantibodies in myasthenia gravis. Journal of the Neurological Sciences, 2015, 348, 241-244.	0.6	45
257	A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle and Nerve, 1990, 13, 407-413.	2.2	44
258	Serological and experimental studies in different forms of myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1413, 143-153.	3.8	44
259	New autoantibody mediated disorders of the central nervous system. Current Opinion in Neurology, 2003, 16, 351-357.	3.6	43
260	Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. Journal of Neuroimmunology, 2005, 162, 184-189.	2.3	43
261	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia, 2010, 51, 1898-1901.	5.1	43
262	Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. JAMA Neurology, 2018, 75, 1519.	9.0	43
263	Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology, 2018, 91, e714-e723.	1.1	43
264	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight, 2019, 4, .	5.0	43
265	Epitopes on Human Acetylcholine Receptor Defined by Monoclonal Antibodies and Myasthenia Gravis Sera. Autoimmunity, 1988, 1, 285-297.	2.6	42
266	Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. Journal of Neurology, 2016, 263, 455-466.	3.6	42
267	Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. Journal of Immunology, 1995, 155, 3683-92.	0.8	42
268	Acetylcholine receptors. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1975, 270, 551-559.	2.3	41
269	CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 718-721.	1.9	41
270	The Structure, Function, and Physiology of the Fetal and Adult Acetylcholine Receptor in Muscle. Frontiers in Molecular Neuroscience, 2020, 13, 581097.	2.9	41

#	Article	IF	CITATIONS
271	Pathogenic Autoantibodies in the Lambert-Eaton Myasthenic Syndrome. Annals of the New York Academy of Sciences, 2003, 998, 187-195.	3.8	40
272	Amnesia, cerebral atrophy, and autoimmunity. Lancet, The, 2003, 361, 1266.	13.7	40
273	Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Developmental Medicine and Child Neurology, 2011, 53, 1058-1060.	2.1	40
274	IgG and Complement Deposition and Neuronal Loss in Cats and Humans With Epilepsy and Voltage-Gated Potassium Channel Complex Antibodies. Journal of Neuropathology and Experimental Neurology, 2014, 73, 403-413.	1.7	40
275	Autoimmune encephalitis new awareness, challenging questions. Discovery Medicine, 2011, 11, 449-58.	0.5	40
276	Antibodies Affecting Ion Channel Function in Acquired Neuromyotonia, in Seropositive and Seronegative Myasthenia Gravis, and in Antibody-mediated Arthrogryposis Multiplex Congenita. Annals of the New York Academy of Sciences, 1998, 841, 482-496.	3.8	39
277	A Role for Autoantibodies in Some Cases of Acquired Non-Paraneoplastic Gut Dysmotility. Scandinavian Journal of Gastroenterology, 2002, 37, 166-170.	1.5	39
278	Antibodies identified by cellâ€based assays in myasthenia gravis and associated diseases. Annals of the New York Academy of Sciences, 2012, 1274, 92-98.	3.8	39
279	The role of muscleâ€specific tyrosine kinase ( <scp>MuSK</scp> ) and mystery of <scp>MuSK</scp> myasthenia gravis. Journal of Anatomy, 2014, 224, 29-35.	1.5	39
280	Compromised fidelity of B ell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	3.7	39
281	NMDA-receptor antibodies alter cortical microcircuit dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9916-E9925.	7.1	39
282	Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clinical and Experimental Immunology, 1982, 49, 266-72.	2.6	39
283	Acetylcholine in Intercostal Muscle from Myasthenia Gravis Patients and in Rat Diaphragm after Blockade of Acetylcholine Receptors. Progress in Brain Research, 1979, 49, 449-458.	1.4	38
284	Aetiological factors in development of myasthenia gravis. Advances in Neuroimmunology, 1994, 4, 355-371.	1.8	38
285	Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. Journal of Neuroimmunology, 2001, 115, 127-134.	2.3	38
286	Encephalitis lethargica: part of a spectrum of post-streptococcal autoimmune diseases?. Brain, 2004, 127, 2-3.	7.6	38
287	Thymoma-Associated Neuromyotonia with Antibodies against Voltage-Gated Potassium Channels Presenting as Chronic Intestinal Pseudo-Obstruction. European Neurology, 2005, 53, 60-63.	1.4	38
288	Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clinical Neurophysiology, 2007, 118, 269-277.	1.5	38

#	Article	IF	CITATIONS
289	Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-monthold child with plasmapheresis and pharmacological immunomodulation. Archives of Disease in Childhood, 2010, 95, 312-312.	1.9	38
290	Acetylcholine receptor l´subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita. Journal of Clinical Investigation, 2001, 108, 125-130.	8.2	38
291	Mechanisms of Action of Antiâ€GM <sub>1</sub> and Antiâ€GQ <sub>1b</sub> Ganglioside Antibodies in Guillainâ€Barré Syndrome. Journal of Infectious Diseases, 1997, 176, S144-S149.	4.0	37
292	Mutations in congenital myasthenic syndromes reveal an varepsilon subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR. Human Molecular Genetics, 2002, 11, 3087-3096.	2.9	37
293	The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates. American Journal of Pathology, 2009, 175, 1536-1544.	3.8	37
294	CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL). Cephalalgia, 2013, 33, 123-129.	3.9	37
295	An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. Journal of Neurology, 2015, 262, 418-424.	3.6	37
296	Monoclonal antibodies to Torpedo acetylcholine receptor. Characterisation of antigenic determinants within the cholinergic binding site. FEBS Journal, 1985, 150, 533-539.	0.2	36
297	Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. Journal of the Neurological Sciences, 1988, 84, 15-28.	0.6	36
298	Response to human acetylcholine receptor α138–199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunology Letters, 1994, 39, 269-275.	2.5	36
299	The Role of Autoantibodies in Lambert-Eaton Myasthenic Syndromeaa. Annals of the New York Academy of Sciences, 1998, 841, 596-605.	3.8	36
300	Myasthenia gravis: diagnostic and management dilemmas. Current Opinion in Neurology, 2001, 14, 583-589.	3.6	36
301	Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. Journal of Neuroimmunology, 2007, 185, 136-144.	2.3	36
302	Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. Neuromuscular Disorders, 2009, 19, 223-228.	0.6	36
303	Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems. Journal of Clinical Immunology, 2010, 30, 97-102.	3.8	36
304	Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. Journal of the Neurological Sciences, 2011, 301, 71-76.	0.6	36
305	Autoantibody screening in subacute cerebellar ataxia. Lancet, The, 2000, 356, 565-566.	13.7	35
306	MuSK antibody-positive, seronegative myasthenia gravis in Korea. Journal of Clinical Neuroscience, 2006, 13, 353-355.	1.5	35

#	Article	IF	CITATIONS
307	Stiff, twitchy or wobbly—are GAD antibodies pathogenic?. Brain, 2008, 131, 2536-2537.	7.6	35
308	Potentially pathogenic autoantibodies associated with epilepsy and encephalitis in children and adults. Epilepsia, 2011, 52, 8-11.	5.1	35
309	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathologica Communications, 2017, 5, 95.	5.2	35
310	Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies. Brain, 2019, 142, 2000-2012.	7.6	35
311	Autoantibodies in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2013, 70, 919.	9.0	34
312	<i>N</i> â€methylâ€ <scp>d</scp> â€aspartate ( <scp>NMDA</scp> ) receptor antibodies encephalitis mimicking an autistic regression. Developmental Medicine and Child Neurology, 2016, 58, 1092-1094.	2.1	34
313	Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors. Current Opinion in Neurology, 2017, 30, 310-316.	3.6	34
314	Approaches for Studying the Pathogenic T Cells in Autoimmune Patients. Annals of the New York Academy of Sciences, 1993, 681, 219-237.	3.8	33
315	Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Current Opinion in Immunology, 1996, 8, 865-871.	5.5	33
316	Physicochemical and immunological studies of the N-terminal domain Ã <sup>-</sup> Âį½of theTorpedoacetylcholine receptor α-subunit expressed in Ã <sup>-</sup> Âį½Escherichia coli. FEBS Journal, 1999, 259, 310-319.	0.2	33
317	Overexpression of Rapsyn in Rat Muscle Increases Acetylcholine Receptor Levels in Chronic Experimental Autoimmune Myasthenia Gravis. American Journal of Pathology, 2007, 170, 644-657.	3.8	33
318	Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. Journal of the Neurological Sciences, 2013, 335, 221-223.	0.6	33
319	Neuronal antibodies in pediatric epilepsy: Clinical features and longâ€ŧerm outcomes of a historical cohort not treated with immunotherapy. Epilepsia, 2016, 57, 823-831.	5.1	33
320	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30649-30660.	7.1	33
321	Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle and Nerve, 1982, 5, S17-20.	2.2	33
322	Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNÎ <sup>3</sup> secretion and cytotoxicity. Journal of Neuroimmunology, 1998, 86, 53-62.	2.3	32
323	Diseases of the neuromuscular junction. Current Opinion in Pharmacology, 2002, 2, 296-301.	3.5	32
324	A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings. Journal of Neurology, 2011, 258, 2268-2270.	3.6	32

#	Article	IF	CITATIONS
325	Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. Sleep, 2017, 40, .	1.1	32
326	Antiâ€acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology, 1988, 38, 1784-1784.	1.1	32
327	ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY SYNTHESIS BY CULTURED LYMPHOCYTES IN MY ASTHENIA GRAVIS: THYMIC AND PERIPHERAL BLOOD CELL INTERACTIONS. Annals of the New York Academy of Sciences, 1981, 377, 393-402.	3.8	31
328	Acetycholine receptor antibody characteristics in myasthenia gravisâ~†Fractionation of α-Bungarotoxin binding site antibodies and their relationship to IgG subclass. Journal of Neuroimmunology, 1983, 5, 1-9.	2.3	31
329	Passive Transfer of Lambert-Eaton Myasthenic Syndrome in Mice: Decreased Rates of Resting and Evoked Release of Acetylcholine from Skeletal Muscle. Journal of Neurochemistry, 1984, 42, 658-662.	3.9	31
330	Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. Journal of Neuroimmunology, 1996, 64, 179-183.	2.3	31
331	Low-voltage-activated A-current controls the firing dynamics of mouse hypothalamic orexin neurons. European Journal of Neuroscience, 2004, 20, 3281-3285.	2.6	31
332	Fetal arthrogryposis and maternal serum antibodies. Neuromuscular Disorders, 2006, 16, 481-491.	0.6	31
333	T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. Journal of Neuroimmunology, 2011, 235, 27-32.	2.3	31
334	Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability. PLoS ONE, 2014, 9, e107274.	2.5	31
335	Glycine receptor antibody mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome. Practical Neurology, 2014, 14, 123-127.	1.1	31
336	Characteristics Of acetylcholineâ€receptorâ€antibody–negative myasthenia gravis in a South African cohort. Muscle and Nerve, 2016, 54, 1023-1029.	2.2	31
337	Acetylcholine in human muscle. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1976, 192, 475-480.	1.8	30
338	Congenital Myasthenic Syndromes. Neuromuscular Disorders, 1993, 3, 183-190.	0.6	30
339	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. Journal of Neuroimmunology, 2014, 271, 66-68.	2.3	30
340	Nâ€methylâ€Dâ€aspartate receptor antibodyâ€associated movement disorder without encephalopathy. Developmental Medicine and Child Neurology, 2014, 56, 190-193.	2.1	30
341	Clycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. Journal of the Neurological Sciences, 2014, 343, 180-182.	0.6	30
342	Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. Journal of Neurology, 2015, 262, 1081-1095.	3.6	30

#	Article	IF	CITATIONS
343	Pathogenic potential of antibodies to the <scp>GABA<sub>B</sub></scp> receptor. Epilepsia Open, 2017, 2, 355-359.	2.4	30
344	The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. EMBO Journal, 1990, 9, 2101-6.	7.8	30
345	Two isoforms of the muscle acetylcholine receptor α-subunit are translated in the human cell line TE671. FEBS Letters, 1991, 295, 116-118.	2.8	29
346	Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. Journal of Neuroimmunology, 1993, 46, 57-65.	2.3	29
347	Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform. Journal of Neuroimmunology, 1999, 98, 112-120.	2.3	29
348	A Comparison of MyoD1 and Fetal Acetylcholine Receptor Expression in Childhood Tumors and Normal Tissues. Journal of Molecular Diagnostics, 1999, 1, 23-31.	2.8	29
349	A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. Human Molecular Genetics, 2004, 13, 2947-2957.	2.9	29
350	<i>Congenital Myasthenic Syndromes and the Formation of the Neuromuscular Junction</i> . Annals of the New York Academy of Sciences, 2008, 1132, 99-103.	3.8	29
351	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733.	7.6	29
352	Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Developmental Medicine and Child Neurology, 2016, 58, 836-841.	2.1	29
353	Plasma cell depletion with bortezomib in the treatment of refractory <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment. European Journal of Neurology, 2018, 25, 1384-1388.	3.3	29
354	The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. American Journal of Pathology, 1998, 152, 437-44.	3.8	29
355	Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 383-387.	1.9	28
356	Antibodies to 1251-glutamic acid decarboxylase in patients with stiff man syndrome Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 395-397.	1.9	28
357	MuSKâ€positive myasthenia gravis is rare in the Polish population. European Journal of Neurology, 2008, 15, 720-724.	3.3	28
358	Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. Journal of the Neurological Sciences, 2014, 343, 82-87.	0.6	28
359	Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS ONE, 2015, 10, e0143558.	2.5	28
360	Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes. Seminars in Neurology, 2018, 38, 344-354.	1.4	28

#	Article	IF	CITATIONS
361	Clinical and Experimental Observations in Patients with Congenital Myasthenic Syndromes. Annals of the New York Academy of Sciences, 1993, 681, 451-460.	3.8	27
362	Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflugers Archiv European Journal of Physiology, 1994, 428, 492-498.	2.8	27
363	Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy. Journal of Neuroimmunology, 2002, 130, 243-247.	2.3	27
364	Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Experimental Neurology, 2015, 270, 29-40.	4.1	27
365	Autoimmune Encephalopathies. Pediatric Clinics of North America, 2015, 62, 667-685.	1.8	27
366	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	2.4	27
367	Immunization against GAD Induces Antibody Binding to GAD-Independent Antigens and Brainstem GABAergic Neuronal Loss. PLoS ONE, 2013, 8, e72921.	2.5	27
368	Myasthenia gravis. Advances in Neurology, 2002, 88, 159-88.	0.8	27
369	Neuroimmune disorders in COVID-19. Journal of Neurology, 2022, 269, 2827-2839.	3.6	27
370	Immunological and pharmacological heterogeneity of α-bungarotoxin binding sites extracted from TE671 cells. Journal of Neuroimmunology, 1988, 19, 149-157.	2.3	26
371	Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration. Journal of Neuroimmunology, 2001, 114, 259-264.	2.3	26
372	Antibodies to Neuronal Targets in Neurological and Psychiatric Diseases. Annals of the New York Academy of Sciences, 2003, 992, 48-55.	3.8	26
373	Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disorders, 2005, 7, 205-11.	1.3	26
374	Choline Acetyltransferase in Skeletal Muscle from Patients with Myasthenia Gravis. Journal of Neurochemistry, 1981, 37, 1081-1088.	3.9	25
375	Human muscle acetylcholine receptor: cloning and expression in <i>Escherichia coli</i> of cDNA for the α-subunit. Biochemical Society Transactions, 1989, 17, 219-220.	3.4	25
376	Relative frequency of VGKC and â€~classical' paraneoplastic antibodies in patients with limbic encephalitis. Journal of Neurology, 2008, 255, 1100-1101.	3.6	25
377	Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease. Journal of Neuroimmunology, 2011, 239, 91-97.	2.3	25
378	Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. Journal of Neurology, 2011, 258, 2176-2180.	3.6	25

#	Article	IF	CITATIONS
379	Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model—Recommendations for methods and experimental designs. Experimental Neurology, 2015, 270, 3-10.	4.1	25
380	Human nicotinic acetylcholine receptor α-subunit isoforms: origins and expression. Nucleic Acids Research, 1993, 21, 5463-5467.	14.5	24
381	Antibodies to Ion Channels in Paraneoplastic Disorders. Brain Pathology, 1999, 9, 285-291.	4.1	24
382	IMMUNOTHERAPY-REVERSED COMPULSIVE, MONOAMINERGIC, CIRCADIAN RHYTHM DISORDER IN MORVAN SYNDROME. Neurology, 2008, 71, 2008-2010.	1.1	24
383	Developments in autoimmune channelopathies. Autoimmunity Reviews, 2013, 12, 678-681.	5.8	24
384	Gerstmann-Straüssler-Scheinker disease. Neurology, 2014, 82, 2107-2111.	1.1	24
385	A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England. Neuroepidemiology, 2019, 53, 93-99.	2.3	24
386	Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation. Journal of Neuroimmunology, 2005, 162, 149-156.	2.3	23
387	Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. Journal of the Neurological Sciences, 2012, 312, 52-56.	0.6	23
388	EEG-confirmed epileptic activity in a cat with VGKC-complex/LGI1 antibody-associated limbic encephalitis. Epileptic Disorders, 2014, 16, 116-120.	1.3	23
389	Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment. Frontiers in Molecular Neuroscience, 2020, 13, 159.	2.9	23
390	Autoimmune disorders of the neuromuscular junction. Neurology India, 2008, 56, 305.	0.4	23
391	Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels. Clinical and Experimental Immunology, 1985, 60, 631-6.	2.6	23
392	Stimulation of human T cells by sparse antigens captured on immunomagnetic particles. Journal of Immunological Methods, 1992, 155, 41-48.	1.4	22
393	Supranuclear gaze palsy in glycine receptor antibodyâ€positive progressive encephalomyelitis with rigidity and myoclonus. Movement Disorders, 2012, 27, 1833-1834.	3.9	22
394	Progressive Encephalomyelitis with Rigidity and Myoclonus: A Syndrome with Diverse Clinical Features and Antibody Responses. European Neurology, 2013, 69, 257-262.	1.4	22
395	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	1.9	22
396	Epilepsy-related psychosis: A role for autoimmunity?. Epilepsy and Behavior, 2014, 36, 33-38.	1.7	22

#	Article	IF	CITATIONS
397	Neuromyelitis optica in a child with Aicardi-GoutiÃ^res syndrome. Neurology, 2015, 85, 381-383.	1.1	22
398	Pediatric Herpes Simplex Virus Encephalitis Complicated by N-Methyl-D-aspartate Receptor Antibody Encephalitis. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e17-e21.	1.3	22
399	Brain-relevant antibodies in first-episode psychosis: a matched case–control study. Psychological Medicine, 2018, 48, 1257-1263.	4.5	22
400	Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis. Journal of Immunological Methods, 1982, 51, 371-381.	1.4	21
401	Motor Nerve Terminal Calcium Channels in Lambert-Eaton Myasthenic Syndrome Annals of the New York Academy of Sciences, 1989, 560, 278-290.	3.8	21
402	Thymus, Thymoma, and Specific T Cells in Myasthenia Gravisa. Annals of the New York Academy of Sciences, 1998, 841, 371-387.	3.8	21
403	Epitopes expressed in myasthenia gravis (MC) thymomas are not recognized by patients' T cells or autoantibodies. Clinical and Experimental Immunology, 1998, 112, 17-20.	2.6	21
404	Myasthenia Gravis. Autoimmunity, 2004, 37, 317-319.	2.6	21
405	Paroxysmal EEG pattern in a child with N-methyl-d-aspartate receptor antibody encephalitis. Developmental Medicine and Child Neurology, 2011, 53, 764-767.	2.1	21
406	Progress in autoimmune epileptic encephalitis. Current Opinion in Neurology, 2016, 29, 151-157.	3.6	21
407	<i>I</i> mmuno <i>g</i> lobuli <i>N i</i> n the <i>T</i> reatment of <i>E</i> ncephalitis (IgNiTE): protocol for a multicentre randomised controlled trial. BMJ Open, 2016, 6, e012356.	1.9	21
408	Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy. Annals of Neurology, 2021, 89, 753-768.	5.3	21
409	Anti-acetylcholine receptor idiotypes in myasthenia gravis analysed by rabbit anti-sera. Clinical and Experimental Immunology, 1985, 60, 637-44.	2.6	21
410	Anti-N-methyl-D-Aspartate-Receptor Encephalitis in a Four-Year-Old Girl. Journal of Pediatrics, 2010, 156, 332-334.	1.8	20
411	ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System. Neuroscience, 2020, 439, 48-61.	2.3	20
412	In vivo Mechanisms of Antibody-Mediated Neurological Disorders: Animal Models and Potential Implications. Frontiers in Neurology, 2019, 10, 1394.	2.4	20
413	Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis. Communications Biology, 2021, 4, 1106.	4.4	20
414	Immune-mediated peripheral neuropathies and voltage-gated sodiums channels. , 1999, 22, 108-110.		19

#	Article	IF	CITATIONS
415	The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arquivos De Neuro-Psiquiatria, 2012, 70, 300-304.	0.8	19
416	Anti-N-Methyl-d-aspartate-receptor encephalitis: Cognitive profile in two children. European Journal of Paediatric Neurology, 2012, 16, 79-82.	1.6	19
417	Autoimmune myasthenia gravis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1465-1468.	1.8	19
418	Narcolepsy and H1N1 vaccination. Current Opinion in Pulmonary Medicine, 2013, 19, 587-593.	2.6	19
419	Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 995-1000.	1.9	19
420	Stiff-Person Syndrome: Autoimmunity and the Central Nervous System. CNS Spectrums, 2001, 6, 427-433.	1.2	18
421	Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. Journal of Neurology, 2010, 257, 920-925.	3.6	18
422	Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 2012, 22, 546-548.	0.6	18
423	Characterisation of a syndrome of autoimmune adult onset focal epilepsy and encephalitis. Journal of Clinical Neuroscience, 2014, 21, 1169-1175.	1.5	18
424	Anti-NMDAR encephalitis misdiagnosed asÂHashimoto's encephalopathy. European Journal of Paediatric Neurology, 2014, 18, 72-74.	1.6	18
425	First reported cases of anti-NMDA receptor encephalitis in Vietnamese adolescents and adults. Journal of the Neurological Sciences, 2017, 373, 250-253.	0.6	18
426	Pitfalls in the detection of N -methyl- d -aspartate-receptor (NMDA-R) antibodies. Clinical Biochemistry, 2017, 50, 354-355.	1.9	18
427	Paediatric myasthenia gravis: Prognostic factors for drug free remission. Neuromuscular Disorders, 2020, 30, 120-127.	0.6	18
428	Idiotype restriction in myasthenia gravis antibodies. Nature, 1981, 290, 293-294.	27.8	17
429	Lambert-Eaton Myasthenic Syndrome IgC: Early Morphologic Effects and Immunolocalization at the Motor Endplate. Annals of the New York Academy of Sciences, 1987, 505, 333-345.	3.8	17
430	Lambert-Eaton syndrome antibodies: reaction with membranes from a small cell lung cancer xenograft. Journal of Neuroimmunology, 1988, 18, 97-104.	2.3	17
431	Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1992, 36, 117-125.	2.3	17
432	Autoantibodies, neurotoxins and the nervous system. Journal of Physiology (Paris), 1995, 89, 129-136.	2.1	17

#	Article	IF	CITATIONS
433	ENDPLATE DESTRUCTION DUE TO MATERNAL ANTIBODIES IN ARTHROGRYPOSIS MULTIPLEX CONGENITA. Neurology, 2009, 73, 1806-1808.	1.1	17
434	Bickerstaff's encephalitis and Miller Fisher syndrome associated with voltageâ€gated potassium channel and novel antiâ€neuronal antibodies. European Journal of Neurology, 2010, 17, 1304-1307.	3.3	17
435	Anti-NMDA Receptor Encephalitis With Atypical Brain Changes on MRI. Pediatric Neurology, 2010, 43, 274-278.	2.1	17
436	Non-paraneoplastic limbic encephalitis characterized by mesio-temporal seizures and extratemporal lesions: A case report. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 446-449.	2.0	17
437	Anti–Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia. Archives of Neurology, 2012, 69, 1064-6.	4.5	17
438	Guillainâ€Barré syndrome associated with <scp>CASPR2</scp> antibodies: two paediatric cases. Journal of the Peripheral Nervous System, 2014, 19, 246-249.	3.1	17
439	Acquired neuromyotonia in thymomaâ€associated myasthenia gravis: a clinical and serological study. European Journal of Neurology, 2019, 26, 992-999.	3.3	17
440	Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophrenia Research, 2020, 222, 455-461.	2.0	17
441	Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, e755-e766.	1.1	17
442	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	3.6	17
443	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-ASO3 Vaccination. PLoS ONE, 2015, 10, e0129555.	2.5	17
444	Amyotrophic lateral sclerosis. An autoimmune disease?. Advances in Neurology, 1995, 68, 59-65.	0.8	17
445	Cloning of cDNA Encoding Human Rapsyn and Mapping of the RAPSN Gene Locus to Chromosome 11p11.2–p11.1. Genomics, 1996, 35, 613-616.	2.9	16
446	MuSK-antibody-positive myasthenia gravis in a South Asian population. Journal of the Neurological Sciences, 2009, 284, 33-35.	0.6	16
447	Introduction to autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 3-14.	1.8	16
448	Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children. European Journal of Paediatric Neurology, 2017, 21, 414-417.	1.6	16
449	Acquired neuromyotonia in children with <scp>CASPR</scp> 2 and <scp>LGI</scp> 1 antibodies. Developmental Medicine and Child Neurology, 2019, 61, 1344-1347.	2.1	16
450	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16

#	Article	IF	CITATIONS
451	Antibodies to neuronal surface antigens in patients with a clinical diagnosis of neurodegenerative disorder. Brain, Behavior, and Immunity, 2021, 96, 106-112.	4.1	16
452	alpha-Bungarotoxin and anti-acetylcholine receptor antibody binding to the human acetylcholine receptor. Advances in Cytopharmacology, 1979, 3, 269-78.	0.3	16
453	Epitopes on human acetylcholine receptor α-subunit: binding of monoclonal antibodies to recombinant and synthetic peptides. Biochemical Society Transactions, 1989, 17, 220-221.	3.4	15
454	Congenital myasthenic syndromes. Current Opinion in Neurology, 1997, 10, 402-407.	3.6	15
455	Muscle Nicotinic Acetylcholine Receptor mRNA Expression in Hyperplastic and Neoplastic Myasthenia Gravis Thymusa. Annals of the New York Academy of Sciences, 1998, 841, 407-410.	3.8	15
456	α -Bungarotoxin binding to human muscle acetylcholine receptor: measurement of affinity, delineation of AChR subunit residues crucial to binding, and protection of AChR function by synthetic peptides. Neurochemistry International, 1998, 32, 427-433.	3.8	15
457	Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder. European Journal of Neurology, 2010, 17, 1105-1107.	3.3	15
458	Survivin Blockade Sensitizes Rhabdomyosarcoma Cells for Lysis by Fetal Acetylcholine Receptor–Redirected T Cells. American Journal of Pathology, 2013, 182, 2121-2131.	3.8	15
459	Guillain-Barré-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle and Nerve, 2013, 48, 836-837.	2.2	15
460	Acute Measles Encephalitis in Partially Vaccinated Adults. PLoS ONE, 2013, 8, e71671.	2.5	15
461	Features of Neuromyelitis Optica Spectrum Disorders and Aquaporin-4 With Myelin-Oligodendrocyte Glycoprotein Antibodies—Reply. JAMA Neurology, 2014, 71, 924.	9.0	15
462	Hypoventilation in glycine-receptor antibody related progressive encephalomyelitis, rigidity and myoclonus. Journal of Clinical Neuroscience, 2014, 21, 876-878.	1.5	15
463	Anti-N-Methyl-D-Aspartate Receptor Encephalitis In A Young Child With Histological Evidence On Brain Biopsy Of Coexistent Herpes Simplex Virus Type 1 Infection. Pediatric Infectious Disease Journal, 2016, 35, 347-349.	2.0	15
464	Antibodies to AMPA receptors in Rasmussen's encephalitis. European Journal of Paediatric Neurology, 2016, 20, 222-227.	1.6	15
465	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. Brain, Behavior, and Immunity, 2019, 81, 665-669.	4.1	15
466	VGKCâ€complex antibody mediated encephalitis presenting with psychiatric features and neuroleptic malignant syndrome – further expanding the phenotype. Developmental Medicine and Child Neurology, 2012, 54, 575-576.	2.1	14
467	Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. Acta Neurologica Scandinavica, 2012, 126, 287-291.	2.1	14
468	Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342.	4.1	14

#	Article	IF	CITATIONS
469	Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e16.	6.0	14
470	Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e121.	6.0	14
471	Autoimmune movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 301-315.	1.8	14
472	Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial. BMC Neurology, 2019, 19, 35.	1.8	14
473	False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 69-72.	2.3	14
474	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	1.3	14
475	Acetylcholine receptor antibodies in the elderly and in Down's syndrome. Journal of Neuroimmunology, 1985, 9, 139-146.	2.3	13
476	Differences in Fine Specificity of Anti-Acetylcholine Receptor Antibodies between Subgroups of Spontaneous Myasthenia Gravis of Recent Onset, and of Penicillamine Induced Myasthenia. Autoimmunity, 1988, 2, 31-37.	2.6	13
477	Fasciculations, Autonomic Symptoms and Limbic Encephalitis: A Thymoma-Associated Morvan's-Like Syndrome. European Neurology, 2005, 54, 235-237.	1.4	13
478	Pediatric Autoimmune Epileptic Encephalopathies. Journal of Child Neurology, 2017, 32, 418-428.	1.4	13
479	Investigation of neuronal auto-antibodies in children diagnosed with epileptic encephalopathy of unknown cause. Brain and Development, 2018, 40, 909-917.	1.1	13
480	Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line. Journal of Physiology, 2019, 597, 3713-3725.	2.9	13
481	Maternal Immunity in Autism Spectrum Disorders: Questions of Causality, Validity, and Specificity. Journal of Clinical Medicine, 2020, 9, 2590.	2.4	13
482	Anti-acetylcholine receptor antibodies induced in mice by syngeneic receptor without adjuvants. Immunology, 1986, 58, 151-5.	4.4	13
483	Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain, 2010, 133, 3164-3165.	7.6	12
484	Limbic Encephalitis Associated With Elevated Antithyroid Antibodies. Journal of Child Neurology, 2014, 29, 769-773.	1.4	12
485	Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis. Journal of Immunology, 1995, 154, 6382-96.	0.8	12
486	Anti-acetylcholine receptor antibody: Use of polyethylene glycol as an aid to precipitation of antibody-receptor complexes in determination of light chain and subclass. Journal of Immunological Methods, 1982, 51, 359-369.	1.4	11

#	Article	IF	CITATIONS
487	A Single Nucleotide Deletion in the e Subunit of the Acetylcholine Receptor (AChR) in Five Congenital Myasthenic Syndrome Patients with AChR Deficiencya. Annals of the New York Academy of Sciences, 1998, 841, 195-198.	3.8	11
488	Neuromyotonia in association with systemic sclerosis. Journal of Neurology, 1999, 246, 976-977.	3.6	11
489	Autoimmune channelopathies: John Newsom-Davis's work and legacy. Journal of Neuroimmunology, 2008, 201-202, 245-249.	2.3	11
490	Anti-NMDA receptor encephalitis: aÂvideo case report. Epileptic Disorders, 2009, 11, 267-269.	1.3	11
491	Autoantibodies and pain. Current Opinion in Supportive and Palliative Care, 2016, 10, 137-142.	1.3	11
492	Autoimmunity in neuropsychiatric disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 269-282.	1.8	11
493	Recurrent Optic Neuritis Associated With MOG Antibody Seropositivity. Neurologist, 2017, 22, 101-102.	0.7	11
494	Paraneoplastic cerebellar degeneration and lambertâ€eaton myasthenia in a patient with merkel cell carcinoma and voltageâ€gated calcium channel antibodies. Muscle and Nerve, 2017, 56, 998-1000.	2.2	11
495	Antibody-mediated central nervous system diseases. Brain and Neuroscience Advances, 2018, 2, 239821281881749.	3.4	11
496	SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	11
497	Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 526-532.	1.9	11
498	Immunology of the neuromuscular junction and presynaptic nerve terminal. Current Opinion in Neurology, 1999, 12, 545-551.	3.6	11
499	[Plasmapheresis for myasthenia gravis]. New England Journal of Medicine, 1978, 298, 456-7.	27.0	11
500	Autoimmunity to acetylcholine receptors in myasthenia gravis. Biochemical Society Transactions, 1991, 19, 180-183.	3.4	10
501	Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells. European Journal of Immunology, 1995, 25, 2119-2122.	2.9	10
502	Identification of phospholipase A2 and neurotoxic activities in the venom of the New Guinean small-eyed snake (Micropechis ikaheka). Toxicon, 1997, 35, 101-109.	1.6	10
503	Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. Journal of Neuroimmunology, 1997, 80, 1-5.	2.3	10
504	Autoantibody testing in encephalopathies. Practical Neurology, 2012, 12, 4-13.	1.1	10

#	Article	IF	CITATIONS
505	Immune-mediated pediatric epilepsies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 111, 521-531.	1.8	10
506	Paraneoplastic cerebellar syndrome and sensory ganglionopathy with papillary thyroid carcinoma. Journal of the Neurological Sciences, 2014, 341, 183-184.	0.6	10
507	Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology, 2016, 86, 692-694.	1.1	10
508	Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 836-847.	2.5	10
509	Maternal-Autoantibody-Related (MAR) Autism: Identifying Neuronal Antigens and Approaching Prospects for Intervention. Journal of Clinical Medicine, 2020, 9, 2564.	2.4	10
510	Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with longâ€standing nodding syndrome: A caseâ€control study. Epilepsia Open, 2021, 6, 297-309.	2.4	10
511	Autoimmune channelopathies: new antibody-mediated disorders of the central nervous system. F1000 Biology Reports, 2009, 1, 61.	4.0	10
512	Immunogenicity of Human Recombinant Acetylcholine Receptor α Subunit: Cytoplasmic Epitopes Dominate the Antibody Response in four Mouse Strains. Autoimmunity, 1994, 18, 113-119.	2.6	9
513	Congenital Myasthenic Syndromes: Studies of the AChR and Other Candidate Genesa. Annals of the New York Academy of Sciences, 1998, 841, 181-183.	3.8	9
514	Seronegative Myasthenia Plasmas and Non-IgG Fractions Transiently Inhibit nAChR Functiona. Annals of the New York Academy of Sciences, 1998, 841, 501-504.	3.8	9
515	An Animal Model of Maternal Antibodymediated Arthrogryposis Multiplex Congenita (AMC)a. Annals of the New York Academy of Sciences, 1998, 841, 565-567.	3.8	9
516	Persistent facial myokymia: an autoimmune aetiology?. Journal of Neurology, 2000, 247, 554-555.	3.6	9
517	Measuring and evaluating the significance of autoantibodies in neurological disorders. Clinical and Applied Immunology Reviews, 2002, 3, 127-151.	0.4	9
518	Lack of association between acetylcholine receptor ? polymorphisms and early-onset myasthenia gravis. Muscle and Nerve, 2004, 29, 436-439.	2.2	9
519	New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin. Journal of Neurology, 2008, 255, 1603-1604.	3.6	9
520	Limbic encephalitis presenting as a post-partum psychiatric condition. Journal of the Neurological Sciences, 2011, 308, 152-154.	0.6	9
521	Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations. Epilepsy Research, 2012, 100, 194-198.	1.6	9
522	Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. Journal of Clinical Neuroscience, 2013, 20, 938-942.	1.5	9

#	Article	IF	CITATIONS
523	Do we need to measure specific antibodies in patients with limbic encephalitis?. Neurology, 2017, 88, 508-509.	1.1	9
524	Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Multiple Sclerosis Journal, 2018, 24, 679-684.	3.0	9
525	In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients. Scientific Reports, 2019, 9, 5591.	3.3	9
526	Neuronal antibody prevalence in children with seizures under 3 years. Neurology, 2020, 95, e1590-e1598.	1.1	9
527	Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice. Neuropathology and Applied Neurobiology, 2021, 47, 316-327.	3.2	9
528	Comparison of N-methyl-d-aspartate receptor antibody assays using live or fixed substrates. Journal of Neurology, 2021, 268, 1818-1826.	3.6	9
529	Acetylcholine Receptor Antibody: Clinical and Experimental Aspects. Novartis Foundation Symposium, 1982, , 225-247.	1.1	9
530	Serial immunoprecipitation assays for interferon(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	2.0	9
531	cDNA and Genomic Clones Encoding the Human Muscle Acetylcholine Receptor. Annals of the New York Academy of Sciences, 1993, 681, 165-167.	3.8	8
532	Neuromyotonia in association with essential thrombocythemia. Journal of the Neurological Sciences, 2000, 173, 78-79.	0.6	8
533	Immunocapture and Identification of Cell Membrane Protein Antigenic Targets of Serum Autoantibodies. Molecular and Cellular Proteomics, 2009, 8, 1688-1696.	3.8	8
534	A clinicoâ€radiological phenotype of voltageâ€gated potassium channel complex antibodyâ€mediated disorder presenting with seizures and basal ganglia changes. Developmental Medicine and Child Neurology, 2012, 54, 1157-1159.	2.1	8
535	Long-term clinical course with voltage-gated potassium channel antibody in Morvan's syndrome. Journal of Neurology, 2013, 260, 2407-2408.	3.6	8
536	Autoantibodies in Japanese patients with ocular myasthenia gravis. Muscle and Nerve, 2021, 63, 262-267.	2.2	8
537	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	2.4	8
538	N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness. Biological Psychiatry, 2016, 79, e61.	1.3	7
539	Autoantibodies to the N-Methyl-D-Aspartate Receptor in Adolescents With Early Onset Psychosis and Healthy Controls. Frontiers in Psychiatry, 2020, 11, 666.	2.6	7
540	Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	7

#	Article	IF	CITATIONS
541	Antibody specificity in myasthenia gravis. Monographs in Allergy, 1988, 25, 33-40.	0.2	7
542	lgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Annals of Neurology, 2000, 47, 504-10.	5.3	7
543	Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective. Frontiers in Immunology, 2022, 13, 833548.	4.8	7
544	4 Acetylcholine receptors and myasthenia gravis. Clinics in Endocrinology and Metabolism, 1983, 12, 57-78.	1.6	6
545	Disorders Affecting the Acetylcholine Receptor: Myasthenia Gravis and Congenital Myasthenia. Journal of Receptors and Signal Transduction, 1987, 7, 599-616.	1.2	6
546	Neuroimmunology of myasthenia gravis. Brain, Behavior, and Immunity, 1988, 2, 346-351.	4.1	6
547	Structural Abnormalities of the AChR Caused by Mutations Underlying Congenital Myasthenic Syndromes. Annals of the New York Academy of Sciences, 2003, 998, 114-124.	3.8	6
548	LEMS IgG Binds to Extracellular Determinants on N-Type Voltage-Gated Calcium Channels, but Does Not Reduce VGCC Expression. Annals of the New York Academy of Sciences, 2003, 998, 196-199.	3.8	6
549	Chapter 16 Antibody-mediated disorders of neuromuscular transmission. Supplements To Clinical Neurophysiology, 2004, 57, 147-158.	2.1	6
550	Myasthenia gravis with MuSK antibodies. Practical Neurology, 2005, 5, 356-359.	1.1	6
551	Voltage-Gated Potassium Channels Autoantibodies in a Child with Rasmussen Encephalitis. Neuropediatrics, 2014, 45, 336-340.	0.6	6
552	Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?. Journal of Neuropathology and Experimental Neurology, 2015, 74, 194-197.	1.7	6
553	Disentangling etiologies of CNS infections in Singapore using multiple correspondence analysis and random forest. Scientific Reports, 2020, 10, 18219.	3.3	6
554	Case report: Headache and neurological deficits with CSF lymphocytosis (HaNDL) associated with P/Q type voltage-gated calcium channel antibodies ( <i>CACNA1A</i> ). Cephalalgia, 2020, 40, 1003-1007.	3.9	6
555	K+-Stimulated Ca2+Influx in Cell Lines Derived from Small Cell Lung Cancer and Neuronal Tumors. Annals of the New York Academy of Sciences, 1989, 560, 294-296.	3.8	5
556	Expression of Muscle Proteins in Thymomas of Patients with Myasthenia Gravisa. Annals of the New York Academy of Sciences, 1998, 841, 411-413.	3.8	5
557	Production of Fab Fragments against the Human Acetylcholine Receptor from Myasthenia Gravis Thymus Lambda and Kappa Phage Librariesa. Annals of the New York Academy of Sciences, 1998, 841, 418-421.	3.8	5
558	Antibodies associated with paraneoplastic neurological disorders. Neurological Sciences, 2005, 26, s3-s4.	1.9	5

#	Article	IF	CITATIONS
559	John Newsom-Davis: clinician-scientist and so much more. Brain, 2011, 134, 3755-3774.	7.6	5
560	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	1.9	5
561	Detection of NMDARs Antibodies in Encephalitis. Methods in Molecular Biology, 2017, 1677, 117-126.	0.9	5
562	Absence of anti-acetylcholine receptor antibodies in Praomys (Mastomys) natalensis. Clinical and Experimental Immunology, 1981, 43, 94-8.	2.6	5
563	Tissue-specific antibodies in myasthenia gravis Journal of Clinical Pathology, 1979, s3-13, 97-106.	2.0	4
564	Immunological aspects of acetycholine receptors. Trends in Neurosciences, 1983, 6, 249-251.	8.6	4
565	Action of antibodies directed against the acetylcholine receptor on channel function at mouse and rat motor end-plates Journal of Physiology, 1988, 399, 577-589.	2.9	4
566	Antibody-mediated neurological disease. Current Opinion in Neurobiology, 1991, 1, 430-435.	4.2	4
567	EAMG Induced in Rabbits by Immunization against Peptides Representing Human AChR ?138?199. Annals of the New York Academy of Sciences, 1993, 681, 295-297.	3.8	4
568	Autoantibodies to voltage-gated potassium channels in acquired neuromyotonia. Neuromuscular Disorders, 1994, 4, S28.	0.6	4
569	Heterogeneity and immunotherapy of specific T-cells in myasthenia gravis. Biochemical Society Transactions, 1997, 25, 665-670.	3.4	4
570	Disorders of the Human Neuromuscular Junction. Advances in Organ Biology, 1997, 2, 315-349.	0.1	4
571	Evidence for an Association between Human Acetylcholine Receptor and Rapsyna. Annals of the New York Academy of Sciences, 1998, 841, 14-16.	3.8	4
572	Antibodies against Muscle-Specific Kinase in Juvenile Myasthenia Gravis. Neuropediatrics, 2003, 34, 110-111.	0.6	4
573	PAW33 Aquaporin-4 M 23 isoform provides a more sensitive assay for aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e32-e32.	1.9	4
574	Surviving stiff-person syndrome: a case report. Journal of Neurology, 2011, 258, 1898-1900.	3.6	4
575	Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis. Laboratoriums Medizin, 2011, 35, 329-342.	0.6	4
576	Prevalence, clinical features and treatment outcomes of patients with myasthenia gravis positive for antibodies to muscle-specific kinase in Thailand. Journal of Clinical Neuroscience, 2013, 20, 707-709.	1.5	4

#	Article	IF	CITATIONS
577	A pilot study on neurological manifestations and antibodies against antigens in children with hematological and other cancers. European Journal of Paediatric Neurology, 2013, 17, 97-101.	1.6	4
578	VGKC-complex antibody encephalitis. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 657-659.	0.5	4
579	Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Optica. JAMA Neurology, 2015, 72, 747.	9.0	4
580	Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21228-21235.	7.1	4
581	Teratogen update: Maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology, 2000, 62, 332-341.	1.6	4
582	The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110664.	1.0	4
583	Temporal lobe seizures, amnesia and autoantibodies - identifying a potentially reversible form of non-paraneoplastic limbic encephalitis. Epileptic Disorders, 2005, 7, 177-9.	1.3	4
584	Limbic Encephalitis: Under-Recognition of Voltage-Gated Potassium Channel Antibodies. European Neurology, 2007, 58, 184-184.	1.4	3
585	Laboratoriums Medizin, 2012, 35,	0.6	3
586	More movements in neuroimmunology. Brain, 2012, 135, 3201-3202.	7.6	3
587	Stiff person syndrome in South Asia. BMC Research Notes, 2016, 9, 468.	1.4	3
588	Voltage-Gated Potassium Channel Antibodies in Slow-Progression Motor Neuron Disease. Neurodegenerative Diseases, 2017, 17, 59-62.	1.4	3
589	Autoimmune neurological disorders-does the age matter?. European Journal of Paediatric Neurology, 2018, 22, 341-343.	1.6	3
590	Standing on the shoulders of giants: 100 years of neurology and epidemic infections. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1129-1131.	1.9	3
591	Autoimmune psychosis â $\in$ 'Authors' reply. Lancet Psychiatry,the, 2020, 7, 123-125.	7.4	3
592	Autoantibodies in neuromuscular transmission disorders. Annals of Indian Academy of Neurology, 2008, 11, 140.	0.5	3
593	Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin. Annals of the New York Academy of Sciences, 1988, 540, 389-391.	3.8	2
594	α-Neurotoxin binding to the human nicotinic acetylcholine receptor. Biochemical Society Transactions, 1990, 18, 889-890.	3.4	2

#	Article	IF	CITATIONS
595	HL A-A2-Restricted T-Cell Line Recognizing an Epitope of the Human Acetylcholine Receptor. Annals of the New York Academy of Sciences, 1993, 681, 276-279.	3.8	2
596	Reflections on the VIth International Congress of Neuroimmunology held at the Edinburgh International Conference Centre, Edinburgh, September 3–7, 2001. Journal of Neuroimmunology, 2002, 124, 1-3.	2.3	2
597	Mechanisms in myasthenia gravis. Drug Discovery Today Disease Mechanisms, 2005, 2, 401-408.	0.8	2
598	Autoantibodies in different forms of myasthenia gravis and in the Lambert–Eaton syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 91, 213-227.	1.8	2
599	Acute disseminated encephalomyelitis associated with positive voltage gated potassium channel complex antibody. Multiple Sclerosis and Related Disorders, 2013, 2, 147-150.	2.0	2
600	Diagnostic algorithm for relapsing demyelinating syndromes of the CNS in children. Lancet, The, 2017, 389, S41.	13.7	2
601	Autoantibody Testing in theÂDiagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases. , 2018, , 153-168.		2
602	Neuronal surface antibodies are common in children with narcolepsy and active movement disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 111-112.	1.9	2
603	Using AChR antibody titres to predict treatment responses in myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 915-915.	1.9	2
604	Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. FEBS Journal, 2000, 267, 6717-6728.	0.2	2
605	Determination of anti-acetylcholine receptor antibodies in myasthenic patients by use of time-resolved fluorescence. Clinical Chemistry, 2002, 48, 549-54.	3.2	2
606	Steroid-responsive recurrent limbic encephalitis associated with small cell lung cancer and neuropil antibodies. Acta Neurologica Belgica, 2011, 111, 139-42.	1.1	2
607	New support for autoimmune basis of myasthenia gravis. Nature, 1975, 256, 10-11.	27.8	1
608	Monoclonal antibodies to the human acetylcholine receptor. Biochemical Society Transactions, 1985, 13, 116-117.	3.4	1
609	Monoclonal antibodies to the α-bungarotoxin-binding site on acetylcholine receptors from Torpedo mamorata. Biochemical Society Transactions, 1985, 13, 117-118.	3.4	1
610	Development of an Adjuvant-Independent Model of Myasthenia Gravis in Mice. Annals of the New York Academy of Sciences, 1987, 505, 806-808.	3.8	1
611	Monoclonal Anti-Acetycholine Receptor Antibodies as Probes for Human Acetylcholine-Receptor in Myasthenia Gravis. Journal of Receptors and Signal Transduction, 1988, 8, 143-159.	1.2	1
612	T-Cell epitopes in patients with myasthenia gravis defined by the use of recombinant polypeptides of the humanacetylcholine receptor. Journal of Autoimmunity, 1989, 2, 903.	6.5	1

#	Article	IF	CITATIONS
613	An in Vitro Model for Disease-specific Immunotherapy in Myasthenia Gravis Using Soluble MHC Class II Bound to AChR-derived Peptide. Annals of the New York Academy of Sciences, 1993, 681, 577-580.	3.8	1
614	Letter to the editor. Journal of Neuroimmunology, 1994, 53, 115.	2.3	1
615	Is the AChR α373–380 sequence a T or B cell epitope in thymoma associated-myasthenia gravis?. Neuromuscular Disorders, 1994, 4, S34.	0.6	1
616	Involvement of cation channels in autoimmune disease. Biochemical Society Transactions, 1994, 22, 488-491.	3.4	1
617	Neuronal Staining Patterns in Sera from Patients with Lambert-Eaton Myasthenic Syndromea. Annals of the New York Academy of Sciences, 1998, 841, 684-686.	3.8	1
618	Neuroprotective autoimmunity—a double-edged sword?. Nature Medicine, 2000, 6, 383-385.	30.7	1
619	A 45-year history of acquired autoimmune neuromyotonia. Journal of Neurology, 2006, 253, 1243-1245.	3.6	1
620	Corrigendum to "Autoimmune channelopathies: John Newsom-Davis's work and legacy: A summary of the Newsom-Davis Memorial Lecture 2008―[J. Neuroimmunol. 201–202 (2008) 245–249]. Journal of Neuroimmunology, 2009, 210, 131.	2.3	1
621	N-methyl-D-aspartate limbic encephalitis: Diagnosis should respect well-recognized criteria. Critical Care Medicine, 2010, 38, 1615-1616.	0.9	1
622	T243 AUTOIMMUNITY AGAINST THE BETA2 ADRENERGIC RECEPTOR AND MUSCARINIC 2 RECEPTOR IN COMPLEX REGIONAL PAIN SYNDROME. European Journal of Pain Supplements, 2011, 5, 48-48.	0.0	1
623	Republished review: Autoantibody testing in encephalopathies. Postgraduate Medical Journal, 2012, 88, 280-289.	1.8	1
624	End of the bed (end of the video) diagnosis: Figure 1. Practical Neurology, 2012, 12, 135-138.	1.1	1
625	Organic neuropsychiatry: a treatable cause of suicidal behaviour. Practical Neurology, 2013, 13, 44-48.	1.1	1
626	N-Methyl-d-aspartate receptor (NMDAR) antibodies in post herpes simplex virus encephalitis (HSVE) neurological relapse. Journal of the Neurological Sciences, 2013, 333, e128.	0.6	1
627	Creutzfeld-Jakob Disease—Reply. JAMA Neurology, 2013, 70, 1589.	9.0	1
628	Cell-surface neuronal antibodies in patients with Japanese encephalitis virus. Journal of Neuroimmunology, 2014, 275, 6-7.	2.3	1
629	Autoantibodies at the neuromuscular junction–Âlink to the central nervous system. Revue Neurologique, 2014, 170, 584-586.	1.5	1
630	Central nervous system antibody-mediated diseases with autonomic involvement – Focus on VGKC-complex (LGI1, CASPR2), NMDAR and GlyR antibodies. Autonomic Neuroscience: Basic and Clinical, 2015, 192, 15.	2.8	1

#	Article	IF	CITATIONS
631	The Importance of Keeping in Mind the Diagnosis of N -Methyl-D-Aspartate Receptor Encephalitis. Biological Psychiatry, 2016, 80, e15.	1.3	1
632	John Newsom-Davis. 18 October 1932—24 August 2007. Biographical Memoirs of Fellows of the Royal Society, 2019, 67, 327-355.	0.1	1
633	Myasthenia Gravis and Related Disorders. , 2020, , 1011-1033.		1
634	Autoimmune Encephalitis—Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes. European Neurological Review, 2014, 9, 87.	0.5	1
635	Genetic and antibody-mediated channelopathies at the neuromuscular junction. Electroencephalography and Clinical Neurophysiology Supplement, 1999, 50, 250-8.	0.0	1
636	Paraneoplastic chronic demyelinating neuropathy and Lambert-Eaton myasthenic syndrome associated with multiple anti-neural antibodies and small-cell lung cancer. Ideggyogyaszati Szemle, 2008, 61, 325-8.	0.7	1
637	Experimental myasthenia gravis — a new autoimmune model. Trends in Biochemical Sciences, 1976, 1, 289-291.	7.5	0
638	Myasthenia gravis — latest developments. Trends in Biochemical Sciences, 1977, 2, N275-N276.	7.5	0
639	ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY HETEROGENEITY IN DIFFERENT FORMS OF MYASTHENIA GRAVIS. Annals of the New York Academy of Sciences, 1981, 377, 895-897.	3.8	0
640	Expression of voltage-gated calcium channels in tumour cell lines of neuroectodermal or other origin. Journal of Neuroimmunology, 1987, 16, 101-102.	2.3	0
641	Epitopes on human ACHR defined by monoclonal antibodies. Journal of Neuroimmunology, 1987, 16, 178-179.	2.3	Ο
642	Plasma from anti-AChR Ab negative MG patients reduces Na+ influx into TE671 cells. Journal of Autoimmunity, 1989, 2, 930.	6.5	0
643	Mouse T and B cell recognition epitopes on the recombinant human muscle acetylcholine receptor α-subunit. Journal of Autoimmunity, 1989, 2, 905.	6.5	0
644	Isolation and expression of cDNAS for the human muscle nicotinic acetylcholine receptor. Journal of Autoimmunity, 1989, 2, 902.	6.5	0
645	BOOK REVIWES. Brain, 1990, 113, 1920-1921.	7.6	0
646	Role of acetylcholine receptor antibody complexes in experimental autoimmune myasthenia gravis. Journal of Autoimmunity, 1991, 4, xxviii.	6.5	0
647	Fine specificity of an AChR-reactive T cell line from a young myasthenic patient. Journal of Autoimmunity, 1991, 4, xi.	6.5	0
648	Acquired neuromyotonia (Isaac's syndrome): Evidence for an antibody-mediated mechanism. Journal of Neuroimmunology, 1991, 35, 68.	2.3	0

#	Article	IF	CITATIONS
649	Binding of acetylcholine receptor α-subunit peptides to HLA-A2. Journal of Neuroimmunology, 1991, 35, 115.	2.3	0
650	Selecting T cell lines in myasthenia gravis (MG) using recombinant human autoantigen. Journal of Neuroimmunology, 1991, 35, 116.	2.3	0
651	Lectins affect ACHR function in TE671 cells: A possible model for seronegative MG plasma. Journal of Neuroimmunology, 1991, 35, 194.	2.3	0
652	Stimulation of Specific T Cells by Human A ChR Adsorbed to Immunomagnetic Particles. Annals of the New York Academy of Sciences, 1993, 681, 288-291.	3.8	0
653	Molecular characterisation of the human muscle nicotinic acetylcholine receptor genes. Neuromuscular Disorders, 1994, 4, S50.	0.6	0
654	Fetal acetylcholine receptor function reduced by serum from asymptomatic mother with history of fetal arthrogryposis. Neuromuscular Disorders, 1994, 4, S19.	0.6	0
655	Single channel properties of human muscle nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. Neuromuscular Disorders, 1994, 4, S47.	0.6	0
656	"Spreading―of B cell determinants in experimental myasthenia gravis induced by acetylcholine receptor peptides. Neuromuscular Disorders, 1994, 4, S45.	0.6	0
657	Lambert-Eaton myasthenic syndrome IgG identifies calcium channel subtypes in neuronal cell lines. Neuromuscular Disorders, 1994, 4, S11.	0.6	0
658	Thymoma epithelial cells can present AChR antigens to specific T cells. Neuromuscular Disorders, 1994, 4, S31.	0.6	0
659	CLONING AND EXPRESSION OF HUMAN S-LAMININ. Biochemical Society Transactions, 1996, 24, 278S-278S.	3.4	0
660	Antibodies specific for fetal AChR induce arthrogryposis multiplex congenita in developing mice: an animal model for transfer of pathogenic antibodies. Journal of Reproductive Immunology, 1997, 34, 95-96.	1.9	0
661	Antibodies to voltage-gated (VG) ion channels and glutamic acid decarboxylase (CAD) in childhood forms of epilepsies. Journal of Neuroimmunology, 1998, 90, 92.	2.3	0
662	[36] Antibodies to ion channels. Methods in Enzymology, 1999, 294, 677-704.	1.0	0
663	Hu and VGCC Antibodies Related to the Prognosis of Small Cell Lung Cancer. Acta Neurologica Scandinavica, 2003, 107, 431-431.	2.1	0
664	Use of Anti-Nerve Antibodies. , 0, , 87-93.		0
665	Paraneoplastic neurological syndromes. State of the art. Journal of Neuroimmunology, 2006, 174, 192-204.	2.3	0
666	Acquired Neuromyotonia Precipitated by Thyroid Surgery and Associated with Antiacetylcholine Receptor Antibodies. European Neurology, 2006, 55, 222-224.	1.4	0

#	Article	IF	CITATIONS
667	John Newsom-Davis, 1932–2007. Nature Clinical Practice Neurology, 2007, 3, 647-647.	2.5	Ο
668	P265 Anti-NMDAR auto-immune encephalitis. European Journal of Paediatric Neurology, 2009, 13, S103-S104.	1.6	0
669	371 EFFECT OF THE INJECTION OF CRPS IgG SERUM FRACTION IN MICE. European Journal of Pain, 2009, 13, S112a.	2.8	Ο
670	PATU1 Characteristic faciobrachial dystonic seizures as an immunotherapy-responsive prodrome to voltage-gated potassium channel antibody-associated limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e24-e24.	1.9	0
671	T242 A SERUM-BASED BIOASSAY FOR THE DIAGNOSIS OF COMPLEX REGIONAL PAIN SYNDROME. European Journal of Pain Supplements, 2011, 5, 48-48.	0.0	Ο
672	138â€Differences in outcomes in neuromyelitis optica between a Japanese cohort and a predominantly Caucasian cohort from the UK. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.91-e1.	1.9	0
673	162â€The association of two rare neurological diseases: a multicentre study of 16 patients with AChR antibody myasthenia gravis and AQP4 antibody neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.118-e1.	1.9	Ο
674	0842â€Myelin-oligodendrocyte glycoprotein antibody as a cause of acute disseminated encephalomyelitis with a neuromyelitis optica-like phenotype in adults. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.152-e1.	1.9	0
675	Paediatric autoimmune encephalitis: evaluation of clinical features, laboratory investigations and outcome. Archives of Disease in Childhood, 2012, 97, A135.1-A135.	1.9	Ο
676	094â€Anti-NMDA receptor antibodies disrupt cortical network activity in vitro. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.42-e1.	1.9	0
677	HLA-DRB1 and HLA-DQB1 allele association to myasthenia gravis in Sudan; an Arabian-African population. Journal of the Neurological Sciences, 2013, 333, e478.	0.6	Ο
678	RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.79-e4.	1.9	0
679	Advances in the clinical science of the motor unit. Current Opinion in Neurology, 2014, 27, 503-505.	3.6	0
680	PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.74-e4.	1.9	0
681	AUTOANTIBODIES IN ALZHEIMER DISEASE;. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e3-e3.	1.9	Ο
682	Autoantibodies to the N-methyl-D-aspartate receptor and seizure susceptibility in mice. Lancet, The, 2014, 383, S111.	13.7	0
683	Myasthenia Gravis and Related Disorders. , 2014, , 777-791.		0
684	Autoantibody-associated autoimmune-encephalitis in Sri Lankan patients. Journal of the Neurological Sciences, 2015, 357, e195.	0.6	0

#	Article	IF	CITATIONS
685	OP87 – 3001: Paediatric neurological syndromes associated with glycine receptor antibodies. European Journal of Paediatric Neurology, 2015, 19, S27.	1.6	0
686	PP14.3 – 2698: Prolonged cortical hyperexcitability during burst-suppression associated with glycine receptor antibodies. European Journal of Paediatric Neurology, 2015, 19, S86-S87.	1.6	0
687	GLYCINE RECEPTOR ANTIBODY—A MARKER FOR NMO/ NON-MS DEMYELINATION?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.36-e4.	1.9	0
688	A PROSPECTIVE CLINICAL AND IMMUNOLOGICAL STUDY OF LATE ONSET MYASTHENIA GRAVIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.49-e4.	1.9	0
689	Long-term outcomes of NMDAR-Ab encephalitis in U.K. cases. European Journal of Paediatric Neurology, 2017, 21, e7-e8.	1.6	0
690	1633â€Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A10.1-A10.	1.9	0
691	Acquired Neuromyotonia. , 2018, , 239-250.		0
692	Autoimmune Encephalitis. , 2019, , 21-43.		0
693	O10.3. EXPOSURE TO COMMON INFECTIOUS PATHOGENS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS: CLINICAL AND IMMUNOBIOLOGICAL ASSOCIATIONS. Schizophrenia Bulletin, 2019, 45, S190-S191.	4.3	0
694	GP230â€Fetal acetylcholine receptor inactivation due to maternal myasthenia gravis: an underrecognised, devastating but potentially preventable and treatable disorder. , 2019, , .		0
695	Slow Channel Syndrome Revisited: 40 Years Clinical Follow-Up and Genetic Characterization of Two Cases. Journal of Neuromuscular Diseases, 2022, , 1-8.	2.6	Ο